Indian Journal of Critical Care Medicine
An open access publication of ISCCM™ 
 
Users online: 47 
     Home | Login 
  About Current Issue Archive Search Instructions Online Submission Subscribe Etcetera Contact  
  NAVIGATE Here 
  Search
 
  Next article
  Previous article 
  Table of Contents
  
 RESOURCE Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (570 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free) 

  IN THIS Article
   References

 Article Access Statistics
    Viewed1650    
    Printed73    
    Emailed0    
    PDF Downloaded212    
    Comments [Add]    

Recommend this journal

 


 
LETTER TO THE EDITOR
Year : 2010  |  Volume : 14  |  Issue : 2  |  Page : 105-106

Cyclophosphamide in alveolar hemorrahge due to leptospirosis


Department of Critical Care Medicine, PD Hinduja National Hospital, Mumbai, India

Date of Web Publication9-Aug-2010

Correspondence Address:
Anand V Joshi
Department of Critical Care Medicine & ICU, PD Hinduja National Hospital and MRC, Veer Savarkar Marg, Mumbai - 400 016
India
Login to access the Email id


DOI: 10.4103/0972-5229.68231

PMID: 20859500

Get Permissions




How to cite this article:
Joshi AV, Kapadia F. Cyclophosphamide in alveolar hemorrahge due to leptospirosis. Indian J Crit Care Med 2010;14:105-6

How to cite this URL:
Joshi AV, Kapadia F. Cyclophosphamide in alveolar hemorrahge due to leptospirosis. Indian J Crit Care Med [serial online] 2010 [cited 2014 Apr 16];14:105-6. Available from: http://www.ijccm.org/text.asp?2010/14/2/105/68231


Dear Editor,

We read with interest the research article Cyclophosphamide in pulmonary alveolar hemorrahage due to leptospirosis by Trivedi et al.[1] We would like to have some clarification regarding the design and findings of the study.

Regarding the methodology of the study, we have a comment and some questions. We disagree with the authors' statement, "in view of the life-threatening nature of the disease, a randomized trial was not possible". We are unclear if this is a prospective observational series with historical controls or a non-randomized controlled trial with contemporary controls. As we understand it, a high mortality of 29/32 was noted in the initial group of patients, and cyclophosphamide was then used in the subsequent 33 patients (of whom 22 survived). Could the authors clarify if they submitted the protocol and got clearance from the Human Research Ethics Committee before the 32 control and 33 study patients, or after the 32 control but before the 33 study patients were enrolled.

We would like the authors to clarify if they used cyclophosphamide only if there was clear evidence of pulmonary alveolar hemorrhage, or if they used it for all patients with severe pulmonary involvement in leptospirosis. A Murray ALI score of ≥ 2.5 could be due to alveolar hemorrhage or due to non hemorrhagic conditions like ARDS, pulmonary edema, atelectasis and secondary bacterial pneumonia. Could the authors specify which criteria they used for identifying the subgroup of those with pulmonary alveolar hemorrhage from patients with other forms of pulmonary complications secondary to leptospirosis.

We would also like to authors to give us information regarding the severity of illness and the need of standard critical care in these patients. We note that NIV was used in all patients. We would like further information as to how may in each group got intubated, how many needed invasive hemodynamic monitoring and inotropes or pressors. We note that none received renal replacement therapy. Could the authors give more information about this considering that there was an 80% renal involvement in both groups, and the overall mortality was 40/65. We would also appreciate it if any of the authors could give us a more definite end point, like 28 day mortality, rather than the follow-up only till the counts returned to normal or the patient was discharged from hospital.

We feel that the concept of using cyclophosphamide for alveolar hemorrhage in leptospirosis has potential but would like more complete data before we start using this promising approach.

 
  References Top

1.Trivedi SV, Vasava AH, Patel TC, Bhatia LC. "Cyclophosphamide in pulmonary alveolar hemorrhage due to leptospirosis". Indian J Crit Care Med 2009;13;79-84.  Back to cited text no. 1      




 

Top
Print this article  Email this article
Previous article Next article
Online since 7th April '04
Published by Medknow